{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:35:25Z","timestamp":1775021725398,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:00:00Z","timestamp":1535328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.afos.2018.08.002","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:16:57Z","timestamp":1536293817000},"page":"102-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation"],"prefix":"10.1016","volume":"4","author":[{"given":"Mizue","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-4186","authenticated-orcid":false,"given":"Soichiro","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2018.08.002_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdm282","article-title":"The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors","volume":"19","author":"Rugo","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.afos.2018.08.002_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.mehy.2011.08.040","article-title":"Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen","volume":"77","author":"Oyan","year":"2011","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.afos.2018.08.002_bib3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.2012.44.7805","article-title":"Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial","volume":"31","author":"Goss","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2018.08.002_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2018.08.002_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.afos.2018.08.002_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.afos.2018.08.002_bib7","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper","volume":"23","author":"izzoli","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.afos.2018.08.002_bib8","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2018.08.002_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.afos.2018.08.002_bib10","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.afos.2018.08.002_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.afos.2018.08.002_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.breast.2009.12.001","article-title":"Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy","volume":"19","author":"Hines","year":"2010","journal-title":"Breast"},{"key":"10.1016\/j.afos.2018.08.002_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.afos.2018.08.002_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CCO.0b013e328347918b","article-title":"New developments for treatment and prevention of bone metastases","volume":"23","author":"Body","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.afos.2018.08.002_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.afos.2018.08.002_bib16","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ctrv.2008.03.005","article-title":"Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies","volume":"34","author":"Coleman","year":"2008","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.afos.2018.08.002_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00776-011-0107-6","article-title":"Women with insufficient 25-hydroxyvitamin D without secondary hyperparathyroidism have altered bone turnover and greater incidence of vertebral fractures","volume":"16","author":"Ikegami","year":"2011","journal-title":"J\u00a0Orthop Sci"},{"key":"10.1016\/j.afos.2018.08.002_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-009-9295-x","article-title":"Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women","volume":"85","author":"Ishijima","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2018.08.002_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00223-013-9763-1","article-title":"Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis","volume":"94","author":"Roux","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2018.08.002_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00774-013-0520-3","article-title":"Serum 25-hydroxyvitamin D below 25 ng\/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women","volume":"32","author":"Tanaka","year":"2014","journal-title":"J\u00a0Bone Miner Metabol"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240552551830058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240552551830058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T07:49:58Z","timestamp":1543477798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240552551830058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S240552551830058X"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2018.08.002","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}